iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming
December 16 2019 - 3:15PM
iBio, Inc. (NYSE AMERICAN:IBIO) presented results of the
application of its new
FastGlycaneering
Development Service™ to enhance potency of recombinant
proteins at last week’s Antibody Engineering & Therapeutics
conference in San Diego, CA. Specifically, the presented data
demonstrated the ability to deploy iBio’s glycan engineering
technologies and plant-based manufacturing platform to rapidly
develop and produce biobetters, such as the biobetter rituximab
(“iBio Rituximab”) product candidate currently being developed in
collaboration with CC-Pharming Ltd.
Dr. Sylvain Marcel, iBio’s Vice President of
Protein Expression Sciences, highlighted laboratory results showing
how iBio’s FastGlycaneering Technology enables
greater N-linked glycosylation customization and control. In the
case of iBio Rituximab, antibody dependent cellular cytotoxicity
was increased 30-fold; potency, as measured by half maximal
effective concentration, was substantially improved versus the
control antibody; and iBio’s glycan engineering methods were shown
to be capable of producing antibodies with more homogeneous and
fully human glycosylation patterns.
“This study demonstrated that our complementary
glycan engineering technology can improve the activity of
therapeutic antibodies, which is instrumental in the development of
antibodies with higher potency,” stated Dr. Marcel. “These data
represent a very positive development within our collaboration with
CC-Pharming and, in addition, highlight iBio’s ability to produce
antibodies with more homogeneous and humanized glycosylation
patterns, which can help our other clients and partners achieve
their target product profiles.”
In addition to joint work on a biobetter
rituximab, iBio and CC-Pharming are undertaking joint product
assessments in other categories that, in some cases, may reach the
commercial stage faster than is possible with therapeutic
antibodies. The companies expect to use iBio’s
FastGlycaneering Technology for any glycoproteins
selected from the initial candidate pool for advancement to
commercial development.
In August 2019, iBio granted to CC-Pharming an
exclusive, royalty-bearing commercial license to iBio Rituximab
product candidates for the territory of China, as well as a
research license to iBio’s FastPharming System™
and know-how for the evaluation of multiple product
opportunities.
About CC-Pharming Ltd.
CC-Pharming is located in Zhongguancun
Biomedical Engineering Transformation Center, Shunyi District,
Beijing, China. The company is specialized in plant molecular
medicine technology research and product development using
proprietary tobacco and lettuce transient expression platforms,
focusing on the use of plant bioreactors for the development of
animal-free, safe, high-value recombinant protein and peptide
product for industrial and clinical applications. The Company
develops innovative indoor vertical farming system for efficient
plant-based expression systems, and offers therapeutic biomedicine,
life science research, cosmetics, and CRO/CMO services to clients
in China. Further information is available at
www.cc-pharming.com.
About iBio
iBio, Inc., is a global leader in plant-based
biologics manufacturing. Its FastPharming System™
combines vertical farming, automated hydroponics, and glycan
engineering technologies to rapidly deliver gram quantities of
high-quality monoclonal antibodies, vaccines, bioinks and other
proteins. The Company’s subsidiary, iBio CDMO LLC, provides
FastPharming Contract Development and
Manufacturing Services via its 130,000 square foot facility in
Bryan, Texas. iBio CDMO also enables innovators to use the
FastPharming System for insourced manufacturing
via its Factory Solutions “design-and-build” services. iBio’s
FastGlycaneering Development Service™ includes an
array of new glycosylation technologies for engineering
high-performance recombinant proteins. Additionally, iBio is
developing its own proprietary products which include its lead
asset, IBIO-100, for the treatment of fibrotic diseases. For more
information, visit www.ibioinc.com.
FORWARD-LOOKING
STATEMENTSSTATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Contact:
Stephen KilmerInvestor Relations(646) 274-3580
skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2024 to May 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From May 2023 to May 2024